|Bid||6.46 x 800|
|Ask||6.47 x 1300|
|Day's Range||6.08 - 6.68|
|52 Week Range||3.28 - 22.47|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 01, 2022 - Aug 05, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.80|
Subscribe to Yahoo Finance Plus to view Fair Value for ESPR
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The big shareholder groups in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) have power over the company. Insiders often...
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced findings from a real-world analysis of more than 400,000 patients at high-risk for atherosclerotic cardiovascular disease (ASCVD). The findings were presented at the National Lipid Association Scientific Sessions in Scottsdale, Arizona. “While professional guidelines